Medical Necessity Assessment for Orencia (Abatacept) IV in Seronegative RA

Patient Selection Criteria

The American College of Rheumatology recommends abatacept for patients with moderate to severe active RA who have had an inadequate response to one or more DMARDs, including methotrexate or TNF inhibitors 1, 2
The Mayo Clinic guidelines suggest that abatacept is an appropriate option for patients with seronegative RA who have failed TNF inhibitors 1

The FDA-approved dose of Orencia IV is 1000 mg every 4 weeks for patients weighing more than 100 kg 2, 3
The patient's weight of 334.6 lb (151.8 kg) requires a dose of 1000 mg IV per FDA labeling 2, 3

Clinical trials demonstrate the efficacy of abatacept in patients with inadequate response to methotrexate and TNF antagonists, with significant improvements in ACR 20/50/70 responses 1, 2
Abatacept is generally well tolerated with low discontinuation rates due to adverse events 1, 2

The patient should be monitored for response objectively, with documentation of tender/swollen joint counts, pain scales, and functional assessments at follow-up visits 4, 3, 2
Reassessment should be scheduled after 3 months (approximately 3 additional infusions beyond loading doses) to evaluate the patient's response to treatment 3, 2

The American College of Rheumatology guidelines recommend abatacept for patients with moderate to severe active RA who have had inadequate response to one or more DMARDs, including methotrexate or TNF inhibitors, as seen in patients who have failed conventional synthetic DMARDs and a TNF inhibitor before initiating abatacept 5
For patients with inadequate response to TNF inhibitors, switching to a non-TNF biologic mechanism, such as T-cell costimulation modulation with abatacept, is conditionally recommended over trying a second TNF inhibitor 5

Abatacept demonstrates an acceptable safety profile with low rates of serious adverse events and low immunogenicity, and is associated with fewer adverse events compared to other biologic/targeted synthetic DMARDs, supporting its use in patients who experienced adverse reactions to prior therapies 5